Cortexin
Cortex polypeptide complex
Cortexin is a polypeptide complex from cerebral cortex, injected, and in routine clinical use in Russia and neighboring countries. It is the one compound in this cohort that an independent group outside the Khavinson school has actually gone looking for — and what they found is the most useful sentence on this page.
Cortexin quick facts
| Reported research dose | 10mg (per course) |
| Route | IM |
| Frequency | 1x Daily · Daily (course) |
| Half-life | Not defined (peptide mixture) |
| Forms | Injectable |
| Evidence level | Human (used clinically abroad) |
Cerebrolysin-adjacent neuro complex — course-based IM, popular for recovery/cognition.
What Cortexin actually is — and why that changes the mechanism
Cortexin is a cortex polypeptide complex — a low-molecular-weight peptide fraction from animal brain tissue. No sequence, no mass, no single structure. It is also the only compound in this cohort that an independent research group outside Russia has ever assessed, which makes it the most informative page in the set even though its own evidence is thin.
The mechanism claim, and where it borrows from. The class story is that short peptides reach the nucleus and modulate transcription. That argument was built for defined molecules of two to four residues — it depends on computed DNA-groove interactions and on the specific chemistry of individual side chains. Cortexin is a mixture. No component of a commercial cortex complex has been identified by mass spectrometry in the public literature, so the mechanism is being applied to a product that has not been shown to contain the molecules the mechanism is about.
What that leaves. A polypeptide fraction with a neurotrophic story and no molecular identity. It may well do something — brain-derived peptide preparations have been used clinically in Russia and eastern Europe for decades — but the mechanistic writing attached to it in the English-language market is imported from a literature about tripeptides, and that import has never been justified.
One more thing worth saying plainly. The class mechanism was written for defined peptides of two to seven residues, and a protein hydrolysate is not that. Cortexin is given intramuscularly, so the first thing it meets is serum protease activity, not a cortical neuron. Nothing published follows it past that point. And because the molecular weight range of the fraction has never been published, two cortex preparations could differ in chain length, charge and peptidase resistance and still both be sold under this name.
What the primary literature on Cortexin actually says
The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis
Alsulaimani RA, Quinn TJ (independent — not the Khavinson group) · Cerebral Circulation – Cognition and Behavior 2021;2:100012 · PMID 36324709
An independent systematic review and meta-analysis of animal-derived nootropics in cognitive disorders. It located one trial of Cortexin, with 80 participants — too few to pool, so no effect size was computed. Across the whole class of included drugs the authors concluded that 'risk of bias was moderate to high, there was imprecision, and certainty of evidence was considered low to very low.' That is not a Russian source grading itself; that is an outside group grading the field.
Peptide Regulation of Gene Expression: A Systematic Review
Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR · Molecules 2021;26(22):7053 · PMID 34834147
The mechanism framing that gets applied to cortex preparations — short peptides reaching the nucleus and modulating transcription — stated as a class claim, not as a finding about this product.
Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers
Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M · International Journal of Molecular Sciences 2022;23(14):7733 · PMID 35887081
Relevant to why Cortexin is injected rather than swallowed: the peptide transporters that carry di- and tripeptides across the gut do not carry a protein hydrolysate.
What is not here. One trial, in an independent systematic review that could not pool it. Searched through Europe PMC, PubMed and Google Scholar on 2 September 2026. Naming the gap is more useful than filling it with a paragraph of hedging.
Why the Cortexin evidence is weak — and what it still showed
Almost every human result in this class comes from one school — Vladimir Khavinson's institute in St Petersburg and the groups around it. That means single-center data, collected by the people who developed the compound, rarely blinded, never pre-registered, and reported across enough endpoints that something was always going to move. Read anything below against that.
Specific to Cortexin. Cortexin is the interesting case because the weakness is not hidden. It has decades of clinical use, an enormous domestic literature, and — when a group outside that literature went looking — one poolable-quality trial in 80 people. Widespread use is not evidence; it is a fact about a health system. The honest position is that Cortexin is neither proven nor disproven and has been sitting in that state for a long time, which is unusual for something this widely prescribed.
What the data does support — and this is the only independently graded evidence in the entire cohort. Alsulaimani and Quinn published a systematic review and meta-analysis of animal-derived nootropics in cognitive disorders, covering Cerebrolysin, Actovegin and Cortexin across 24 randomized trials and 2,245 participants. They are not the Khavinson group and have no stake in the compounds.
For Cortexin they located one trial with 80 participants — too few to pool, so no effect size was computed. Their reading of the available data was that it “suggested potential efficacy and no safety concerns”. Their assessment across all included studies was that “risk of bias was moderate to high, there was imprecision, and certainty of evidence was considered low to very low”, and that the effects demonstrated were “modest and probably less than would be considered clinically relevant”.
Read both halves. An outside group looked, found a real randomized trial, and did not find it fraudulent or null — they found it too small and too weakly designed to conclude from. That is a materially different position from every other compound in this cohort, and it is better news than most of them get. It is also nowhere near proof.
The specific epistemic position: one randomized trial, independently reviewed, judged low-certainty and clinically marginal. Not disproven, and — unusually here — not unexamined either.
What is actually measured, and what is not. Measured by an independent group in 2021: one randomized controlled trial of this cortex preparation. The same review graded Cerebrolysin and Actovegin alongside it, across 24 trials, and put certainty of evidence at low to very low. Cerebrolysin is the best-studied compound in that group and it still landed in the same low-certainty band. The review reported no safety concerns in the data it could reach. One more piece of arithmetic worth doing: that single trial contributes roughly 4% of the participants in the review, so 96% of the evidence people cite for this drug class is about two other drugs. Now the column nobody prints. No pharmacokinetic study of a cortex polypeptide complex exists in humans. The plasma half-life of its components has never been measured. Its clearance from serum has never been quantified. An injected fraction meets a peptidase-rich serum compartment within minutes, and nothing describes what survives it. No component of the fraction has been identified, so nothing can be checked against the nuclear-entry claim. Transcription in cortical tissue has never been read out under this product. Chromatin has never been examined under it either. Nothing shows a component reaching a neuronal nucleus. And no imaging or tracer study places any of it inside the brain at all.
Not proven is not the same as disproven. Everything above says the evidence is weak. None of it says the compound does nothing. There is no adequately powered trial that ran and came back null, because outside Russia there is essentially no trial at all — this class is unfunded, not failed. A reader who leaves thinking “disproven” has learned something false, and so has one who leaves thinking “proven”.
Cortexin pharmacokinetics — how much of it actually gets in
Why the half-life reads “Not defined (peptide mixture)”, and why that is where the writing should start rather than stop. A half-life describes the clearance of one compound. A mixture has as many clearance curves as components. The Vault's answer is literally correct and completely uninformative.
What can be reasoned instead. Peptides in the fraction meet serum aminopeptidases like anything else and the short ones clear in minutes. The proposed mechanism does not require persistence — a transcriptional or trophic signal outlasts the molecule that triggered it — so short clearance is not an objection. What it does mean is that measuring the drug is pointless and the only useful measurements are downstream.
Route, and why it is injectable. Cortexin is given intramuscularly, and that is consistent with the pharmacology rather than arbitrary. An injection is 100% bioavailable by definition and skips the gut wall and hepatic first-pass entirely. The named mechanism by which an intact peptide crosses the intestine is PEPT1, which carries di- and tripeptides — not a protein hydrolysate. An oral cortex complex would have no mechanism behind it, and this product does not pretend otherwise.
The step nobody addresses: the blood-brain barrier. The claimed target is brain, and an intramuscular peptide fraction has to cross the blood-brain barrier to get there. No published study measures central exposure for this preparation. That is the single largest unmeasured step on this page, and it is upstream of every clinical claim made for the product.
The ratio the catalog itself implies. Across this class, the oral products carry a median of roughly 10x more material per day than the injectable ones. Nobody arrived at that by measuring absorption — no oral bioavailability figure has been published for any compound in this family — but the gap is the vendors' own implicit answer to the question: swallowing it is assumed to deliver a small fraction of what an injection delivers, and an injection is fully bioavailable by definition. Treat that as a bound on the plausible exposure, not as a measurement, because a measurement is exactly what is missing.
What would have to be true for Cortexin to work
What would have to be true. The peptide fraction would have to contain active components; those would have to survive intramuscular administration and serum peptidases; cross the blood-brain barrier in quantity — never measured; and produce a cognitive change large enough to detect on a standard instrument. The independent review found one trial suggesting the last step and could not pool it. Everything before it is unaddressed.
The right test is the one the independent reviewers implicitly asked for: a second, larger, properly blinded trial with a validated instrument.
- Prediction 1 — MoCA. should improve in a defined deficit population, against a control arm, over a treatment course. The comparator matters more than the instrument here. Cognitive scores improve on repeat testing from practice alone, which is exactly why a single-arm before/after proves nothing.
- Prediction 2 — hs-CRP (High-Sensitivity C-Reactive Protein). no directional prediction; a rise is a reason to stop. Injected protein hydrolysates carry an immunogenicity question that a small-molecule drug does not.
- Prediction 3 — ESR (Sed Rate). same. Paired with hs-CRP so a single odd value does not get over-read.
Run these before and after, not after alone. A single post-course number tells you what your body is doing, not what Cortexin did to it — and that difference is the entire point of testing.
Cortexin versus the alternatives
Cortexin versus Cerluten. Both are CNS-directed peptide complexes with no molecular identity. The difference is that an independent group located a randomized trial of Cortexin and located nothing for Cerluten — the review's own products were Cerebrolysin, Actovegin and Cortexin, and Cerluten was not among them. On evidence Cortexin is straightforwardly the better-supported of the two, and that is worth saying plainly because the two products are otherwise sold interchangeably.
And against the credible alternative. The same review covered Cerebrolysin, which has far more trial data than Cortexin — 24 trials across the whole review, most of them not Cortexin's — and still came out at low to very low certainty with clinically marginal effects. That is the honest ceiling for this entire drug class. For cognitive decline specifically, the interventions with real outcome data remain blood pressure control, hearing correction, exercise and sleep.
What you are actually buying when you buy Cortexin
Cortexin is an extract, not a molecule. A certificate of analysis can establish sterility, endotoxin, total protein and the absence of named contaminants. It cannot establish identity, because there is no formula to check — the product is defined by its process. Two clean certificates can sit on two different mixtures.
And that is why the one good trial does not transfer freely. The trial the independent reviewers found tested a specific manufacturer's preparation. With no assay that can compare one cortex complex to another, there is no way to establish that a different vial is the same product. That caveat is larger than the usual purity discussion, and it applies to every extract in this catalog.
A cortex hydrolysate is defined by its process, not its structure. The questions that actually discriminate between products are the source species, whether the material is certified free of transmissible spongiform encephalopathy risk, and the sterility and endotoxin figures. A purity percentage on a hydrolysate is a number without a referent.
Where to get Cortexin
Buy Cortexin at RUPharma →The evidence for Cortexin
Graded by what exists behind each claim.
Human clinical evidence
- The human record is Soviet and post-Soviet clinical work — real patients and real endpoints, published in Russian and rarely replicated to Western standards.
📊 Correlative data
- Registered and widely prescribed in Russia for stroke recovery, TBI and pediatric developmental conditions, with Russian trials behind those registrations. No Western regulator has assessed it and no independent replication exists, which is the same position as every bioregulator here.
- Used in courses of ten to twenty intramuscular injections, which is the protocol the Russian studies used.
🧪 Theoretical / extrapolated
- A polypeptide fraction from bovine or porcine cerebral cortex, proposed to be neurotrophic and to modulate the balance of excitatory and inhibitory neurotransmission.
- Same extract problem as Cerebrolysin — a preparation rather than a compound. The mechanistic claims are plausible for a mixture of brain-derived peptides and unverifiable for any specific one.
What that tier rests on here. The tier above is the only one in this cohort that an independent group outside Russia has graded. They found one randomized trial of 80 participants, too few to pool, and rated the certainty of evidence across the whole drug class low to very low.
How to read the Soviet clinical series →
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
Cell, rodent, human — and where it stops
Cortexin is the only product in this entire catalog whose distribution has actually been measured. Kurkin 2021, in PLoS One, labeled it radioactively and gave it to mice: it crossed the blood-brain barrier and reached brain concentrations equal to 6–8% of whole blood. Every other page in this class argues about whether a charged peptide could ever cross a membrane. One product stopped arguing and put a number on it.
The same paper contains the result that cuts hardest against the class's own story. Cortexin was screened against a receptor panel and bound strongly to AMPA receptors (80.1%) and kainate receptors (73.5%), moderately to mGluR1 (49.0%), GABA-A1 (44.0%) and mGluR5 (39.7%). That is a glutamatergic and GABAergic profile — a classical receptor drug. It is not the DNA-binding, gene-expression mechanism this class is sold on, and the finding belongs to the people who tested it, not to a critic.
In rodents, head to head. The same study ran middle cerebral artery occlusion and carotid stenosis models against Cerebrolysin and Actovegin. Cortexin at 1 or 3 mg/kg/day and Cerebrolysin at 538 or 1614 mg/kg/day both improved neurological recovery; Actovegin less so. Cortexin matched Cerebrolysin at roughly one five-hundredth of the mass. Kurkin 2025 extends it to developmental-delay models, and Zarubina 2011 is the older chronic-ischemia work.
Independently, and where it stops. Yazar 2023 is a Turkish group with no St Petersburg connection, reporting that Cortexin protected cultured rat sensory neurons against high-glucose injury. Against that, Alsulaimani 2021 pooled the human trials of animal-derived nootropics and graded the certainty low. So: real animal pharmacology, a measured brain concentration, an independent cell replication — and a human evidence base that a systematic review will not stand behind.
What nobody has tested yet
What is in it. A receptor panel that lights up at AMPA and kainate says something in the vial is a glutamate-receptor ligand. Nobody has published the fractionation that would name it. Running the preparation through liquid chromatography with mass spectrometry and re-testing the fractions is standard analytical chemistry, and it would answer the single most interesting question about this product: is the active principle a peptide at all, or a free amino acid — glutamate itself — carried along by the extraction.
A blinded human trial with a cognitive endpoint. The meta-analysis exists; what it lacks is anything to pool. MoCA or Trail Making, a placebo arm, and pre-registration would move this compound out of the low-certainty bracket in a single study, and it is a registered medicine in its home market, so the infrastructure exists.
Extrapolation, labeled as such. If the AMPA and kainate binding is the real mechanism, three predictions follow that nobody has tested: the effect should be acute rather than cumulative, it should be blocked by an AMPA antagonist, and it should carry the liability that goes with glutamatergic drugs — a lower seizure threshold in susceptible people. That last one is a safety hypothesis, not a reported adverse event, and it has never been looked for.
Sources read for this page
- Kurkin DV. Neuroprotective action of Cortexin, Cerebrolysin and Actovegin in acute or chronic brain ischemia in rats. PLoS One 2021 · PMID 34260655
- Kurkin DV. Neurotropic Effects of Cortexin on Models of Mental and Physical Developmental Delay. Biomedicines 2025 · PMID 40299434
- Yazar U. Cortexin Ameliorates High Glucose-Induced Neuropathy in Cultured Rat Sensory Neurons. Neuroendocrinology 2023 · PMID 37080184
- Alsulaimani RA, Quinn TJ (independent — not the Khavinson group). The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis. Cerebral Circulation – Cognition and Behavior 2021;2:100012 · PMID 36324709
- Zarubina IV, Shabanov PD. [Cortexin and cortagen as correcting agents in functional and metabolic disorders in the brain in chronic ischemia]. Eksperimental'naia i Klinicheskaia Farmakologiia 2011;74(2):8-15 [Russian] · PMID 21476278
- Khavinson VKh. Peptides tissue-specifically stimulate cell differentiation during their aging. Bulletin of Experimental Biology and Medicine 2012 · PMID 22808515
Cortexin — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- This group acts directly on established CNS receptors — GABA-B (phenibut), serotonergic and histaminergic (trazodone, doxepin), beta-adrenergic (propranolol), dopaminergic (cabergoline, apomorphine). These are pharmacological drugs, not research peptides, and the predicted problems are the known ones for each receptor.
- Phenibut is the one that needs saying plainly: it is physically addictive. GABA-B agonism produces tolerance within days of regular use, and withdrawal is genuinely severe — anxiety, insomnia, tremor, and in heavy users, psychosis and seizures. It is closer to a benzodiazepine than to a nootropic in this respect, and it is sold as though it were the latter.
- Propranolol blunts the physical symptoms of adrenaline. That predicts the useful effect and also the problem — it blunts the training response and masks hypoglycemia.
- Dopamine agonists predict nausea, orthostatic hypotension and, at the doses used in Parkinson's, impulse-control problems. Cabergoline's half-life is very long, so effects persist well past a dose.
What has actually been reported
- Phenibut dependence and withdrawal are well documented in case reports and poison-center data.
- Trazodone: sedation, orthostatic hypotension, and rarely priapism — which is a medical emergency.
- Abrupt propranolol cessation causes rebound tachycardia and hypertension. Do not stop a beta-blocker suddenly.
- Cabergoline at high cumulative doses is associated with cardiac valve changes; at the low doses used for prolactin this has not been shown.
How to reduce the risk
Same mechanism as the prediction.
- For phenibut, the only reliable mitigation is frequency: occasional use does not produce dependence, regular use does. There is no dose that makes daily use safe.
- Taper anything in this group rather than stopping abruptly.
- Take the first dose of anything with orthostatic effects at home, sitting down.
What it does to your bloodwork
A fact about the assay.
- Prolactin if using cabergoline (it is usually why you are). Otherwise blood pressure and heart rate are the monitoring that matters.
Don't run this if
- You already take a sedative, a benzodiazepine, or drink regularly — the CNS depressant effects are additive and this is where respiratory depression comes from.
- You are on an antidepressant and considering trazodone — serotonergic combinations need a prescriber, not a forum.
The honest unknown
- Most of this group is well characterized for its licensed use. What is NOT characterized is the off-label use most people here are making of it, at doses and durations nobody studied.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Cortexin — safety specifics for this compound
Specific to Cortexin: it is the one compound in this cohort with an independent safety read, and it came back clean — the systematic review reported “no safety concerns” across the data it could locate. That is a real, if limited, reassurance and it should be stated as plainly as the criticisms. The limits are that it rests on a single trial, n=80 — too few for Alsulaimani and Quinn to pool against the n=2,245 across the 24 randomized trials in the rest of their review — and that a brain-derived animal tissue preparation carries the protein-allergy and immunogenicity considerations that come with any animal-source biologic and not with a synthetic peptide.
Cortexin — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Cortexin moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Most of this class has no predicted marker movement at all, and saying so is more useful than listing markers that will not move.
What to do: A baseline liver panel is reasonable for anything taken daily and long-term. Beyond that there is nothing specific to chase.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Needle gauge and injection site
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Cortexin in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Cortexin
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| TSH (Thyroid-Stimulating Hormone) | Thyroid disease imitates every cognitive complaint there is |
| Vitamin B12 | Deficiency causes fog long before it causes anemia |
| Methylmalonic Acid (MMA) | Catches the deficiency a normal B12 hides |
| Ferritin | Low iron flattens cognition at levels most labs call fine |
| Vitamin D (25-Hydroxy) | Commonly low, cheap to correct, associated with mood |
The Brain Fog & Cognition panel covers these in one order — 12 markers, $233.06 with the discount applied.
Check results you already have → · All 103 markers A–Z
Cortexin — frequently asked questions
Is Cortexin a peptide or an extract?
An extract — a peptide complex from cerebral cortex, not a single defined molecule. That is why a certificate of analysis cannot confirm its identity the way it can for a synthetic peptide.
Is there a human trial of Cortexin?
One trial, in an independent systematic review that could not pool it.
What should I measure if I run Cortexin?
Before and after, not after alone. The falsifiability section on this page names the specific markers, the direction each should move and the timescale — and says what a null result would rule out.
References & further reading
- Alsulaimani RA, Quinn TJ (independent — not the Khavinson group) — The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis · Cerebral Circulation – Cognition and Behavior 2021;2:100012 · PMID 36324709
- Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR — Peptide Regulation of Gene Expression: A Systematic Review · Molecules 2021;26(22):7053 · PMID 34834147
- Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M — Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers · International Journal of Molecular Sciences 2022;23(14):7733 · PMID 35887081
What Cortexin is used for
Cortexin appears under 1 goal in the goal router.
Related Cognitive & Mood compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.